Determinants of drug action can be broadly divided into two areas: pharmacokinetics (Does the drug research the target site?) And pharmacodynamics (Once the drug reaches its target site, does the drug bind to its receptor and influence that receptor's signaling and action?). This UCSD/Celera pharmacogenomics center will probe pharmacodynamic determinants of human drug responses. Our focus is human autonomic cardiovascular drug responses in both the systemic and pulmonary circulations. To achieve this focus on the pharmacodynamics of autonomic cardiovascular responses, we have developed an initial phenotyping strategy to emphasize regional (rather than systemic) vascular responses, so as to remove pharmacokinetic and baroreflex variables from their confounding influence, and thereby to isolate and focus upon pharmacodynamic (receptor, post-receptor, and effector) determinants of drug responses. Phenotyping projects 1-> generate information and samples which flow systematically through 7 cores (A-> G), to achieve center goals. The regional responses are characterized in the pulmonary (Phenotyping project 1), renal (Phenotyping project 2), forearm (Phenotyping project 3) and post-synaptic (Phenotyping projects 2&4) responses are studied. This center will evaluate both diagnostic (Phenotyping projects 1->) and therapeutic )Phenotyping projects 1&2; Core G) drug responses. Diagnostic drug responses will allow us to more effectively and """"""""cleanly"""""""" probe receptor and post-receptor signaling, thereby providing rigorous pharmacodynamic insights to be applied later to therapeutic drug responses in humans. Diagnostic responses should allow definition of which SNP alleles contribute to variation in signaling in a particular pathway. We hypothesize that agonist responses, obtained under carefully defined circumstances in regional circulatory beds (pulmonary, renal, forearm, hand), will lead to the discovery of associated SNP alleles which will ultimately yield diagnostic tools to predict therapeutic drug responses (in particular, for antagonists at the same receptors). SNPs will be productive UCSD collaboration with Celera Genomics, a pioneer in large-scale human genome sequencing. The functional significance of discovered SNP alleles will be verified in vitro (Cores D&E) and in experimental organisms (Core F). Finally, such SNP alleles will then be tested in human drug response trials (Core G) to answer the question: Does SNP stratification predict therapeutic drug response in large, prospective, randomized, controlled clinical trials?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HL069758-03
Application #
6652536
Study Section
Special Emphasis Panel (ZRG1-PHRA (01))
Program Officer
Goldman, Stephen
Project Start
2001-09-13
Project End
2005-08-31
Budget Start
2003-09-01
Budget End
2004-08-31
Support Year
3
Fiscal Year
2003
Total Cost
$2,933,291
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Hightower, C Makena; Zhang, Kuixing; Miramontes-González, José P et al. (2013) Genetic variation at the delta-sarcoglycan (SGCD) locus elevates heritable sympathetic nerve activity in human twin pairs. J Neurochem 127:750-61
Papp, Audrey C; Pinsonneault, Julia K; Wang, Danxin et al. (2012) Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One 7:e31930
Davis, Jason T; Rao, Fangwen; Naqshbandi, Dalal et al. (2012) Autonomic and hemodynamic origins of pre-hypertension: central role of heredity. J Am Coll Cardiol 59:2206-16
Gong, Yan; Beitelshees, Amber L; Cooper-DeHoff, Rhonda M et al. (2011) Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease. Circ Cardiovasc Genet 4:169-78
Lobmeyer, Maximilian T; Wang, Liewei; Zineh, Issam et al. (2011) Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics 21:42-9
Price, Elvin Tyrone; Pacanowski, Michael A; Martin, Michael A et al. (2011) Liver X receptor ? gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. Pharmacogenet Genomics 21:333-40
Gayen, Jiaur R; Zhang, Kuixing; RamachandraRao, Satish P et al. (2010) Role of reactive oxygen species in hyperadrenergic hypertension: biochemical, physiological, and pharmacological evidence from targeted ablation of the chromogranin a (Chga) gene. Circ Cardiovasc Genet 3:414-25
Niu, Yuxin; Gong, Yan; Langaee, Taimour Y et al. (2010) Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Circ Cardiovasc Genet 3:548-55
Johnson, A D; Gong, Y; Wang, D et al. (2009) Promoter polymorphisms in ACE (angiotensin I-converting enzyme) associated with clinical outcomes in hypertension. Clin Pharmacol Ther 85:36-44
Gayen, Jiaur R; Saberi, Maziyar; Schenk, Simon et al. (2009) A novel pathway of insulin sensitivity in chromogranin A null mice: a crucial role for pancreastatin in glucose homeostasis. J Biol Chem 284:28498-509

Showing the most recent 10 out of 72 publications